ClinicalTrials.gg
CompletedNCT03013439Updated Dec 12, 2017

Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)

A Phase 1 interventional study of Iron Isomaltoside in Anemia, Deficiency Diseases and Anemia, Iron Deficiency, sponsored by Pharmacosmos A/S. Completed at 1 site in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2017-12-12.

Primary conditionAnemia, Iron-DeficiencyRegistry: AnemiaReclassifiedWhy we changed it
Registry
Anemia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Anemia, Iron-Deficiency
Why
  1. The study's listed conditions name Anemia, Iron-Deficiency, a narrower term within Anemia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pharmacosmos A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency — 9 open to participants now, 9 under way, 4 of them phase 3. iron isomaltoside 1000 · Anemia, Iron-Deficiency.

Enrollment
30th of 32
24 · median 121
Started
2017
with 4 others
Phase 1
2 of 32
1 open now
Registered
12th of 32
by date
Lead sponsor
13 of 32
Pharmacosmos A/S

Among the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, this one is the 30th largest by enrollment, is one of 5 that started in 2017, is one of 2 in phase 1, and was the 12th registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

9 of the 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency are open now, in 6 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About iron isomaltoside 1000

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing iron isomaltoside 1000 in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The trial is an open-label, 4 cohorts, sequential, dose-escalating, single dose trial.

Read the detailed description

IDA is highly prevalent in subjects with cancer and gastrointestinal diseases such as inflammatory bowel diseases, menstruating or pregnant women, and subjects who have undergone bariatric procedure. IDA can have a substantial medical and quality of life (QoL) burden on the subjects, and treatment of these subjects includes controlling the bleeding and replenishing lost iron.

03

Conditions studied

  • Anemia
  • Deficiency Diseases
  • Anemia, Iron Deficiency
  • Hematologic Disease
  • Iron Metabolism Disorders
04

In context

Anemia, Iron-Deficiency Reclassified

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

This study's enrollment of 24 is below the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.

Browse Anemia, Iron-Deficiency studies →

Lead sponsor

Pharmacosmos A/S is the lead sponsor of 36 studies on the registry; 5 are open to participants now.

Compared within Anemia, Iron-Deficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Japanese man or woman ≥ 20 years, \< 65 years of age
  2. of ≥ 9.0 g/dL, \< 12.0 g/dL for women and \< 13.0 g/dL for men
  3. Serum ferritin \< 25 ng/mL
  4. TIBC ≥ 360 μg/dL
  5. Body weight ≥ 50 kg
  6. Willingness to participate and signing the form

Exclusion criteria

Exclusion criteria include:

  1. Anemia caused by conditions other than iron deficiency
  2. Cancer
  3. IV or oral iron treatment, or blood transfusion 4 weeks prior to screening
  4. Erythropoiesis stimulating agent (ESA) treatment prior to screening
  5. Imminent expectation of blood transfusion on part of treating physician
  6. Iron overload or disturbances (e.g. hemochromatosis and hemo-siderosis)
  7. Known reaction to iv iron preparations
  8. Decompensated liver cirrhosis or active hepatitis
  9. Active acute or chronic infections
  10. Pregnant or nursing women.
  11. Planned elective surgery during the trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    cohort 1 iron isomaltoside

    treated with first dose level of iron isomaltoside

    Drug: Iron Isomaltoside

  • Experimental
    cohort 2 iron isomaltoside

    treated with second dose level of iron isomaltoside

    Drug: Iron Isomaltoside

  • Experimental
    cohort 3 iron isomaltoside

    treated with third dose level of iron isomaltoside

    Drug: Iron Isomaltoside

  • Experimental
    cohort 4 iron isomaltoside

    treated with fourth dose level of iron isomaltoside

    Drug: Iron Isomaltoside

Interventions

07

What researchers measure

Primary outcomes

  1. Proportion of adverse events

    Proportion of adverse events will be collected and evaluated for relatedness, severity, seriousness, and expectedness.

    Time frame: 1 week

Secondary outcomes

  1. Maximum plasma drug concentration [Cmax]

    Time frame: 1 week

  2. Area Under the Curve [AUC]

    Time frame: 1 week

  3. Time to reach one-half of the maximum drug concentration [T1/2]

    Time frame: 1 week

  4. Time to reach maximum drug concentration [Tmax]

    Time frame: 1week

  5. Change in concentration of hemoglobin (g/dL)

    Time frame: 1 week

  6. Change in concentration of serum ferritin (ng/mL)

    Time frame: 1 week

  7. Change in concentration of total iron binding capacity (μg/dL )

    Time frame: 1 week

  8. Change in concentrations of transferrin saturation (%)

    Time frame: 1 week

08

Study locations

1 site
  • Ikebukuro
    Tokyo, 171-0014, Japan
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Jun 2017, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2016
First posted
Jan 6, 2017
StartActual
Jan 6, 2017
Primary completionActual
Jun 4, 2017
CompletionActual
Jun 4, 2017
Last update
Dec 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03013439
Lead sponsor
Pharmacosmos A/S
Responsible party
Sponsor
First posted
Jan 6, 2017
Start date
Jan 6, 2017
Primary completion
Jun 4, 2017
Completion
Jun 4, 2017
Last update
Dec 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron isomaltoside 1000

Start the discussion